Litigation Details for Gilead Sciences, Inc. v. Kappos (E.D. Va. 2012)

Gilead Sciences, Inc. v. Kappos (E.D. Va. 2012)

Docket		Date Filed	2012-09-27
Court	District Court, E.D. Virginia	Date Terminated	2013-10-03
Cause	35:154 AIA Appeal of Patent Term Adjustment Determination	Assigned To	Liam O'Grady
Jury Demand	None	Referred To	Ivan D. Davis
Parties	GILEAD SCIENCES, INC.
Patents	8,148,374
Attorneys	Ahmed Jamal Davis
Firms	Fish & Richardson PC (DC)
Link to Docket	External link to docket

Details for Gilead Sciences, Inc. v. Kappos (E.D. Va. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-09-27				External link to document

Gilead Sciences v. Kappos, 1:12-cv-01090: Litigation Summary and Patent-Term Analysis

Last updated: September 1, 2026

Gilead Sciences, Inc. v. Kappos was a U.S. District Court for the District of Columbia action over patent-term adjustment, not a generic-infringement case. Gilead challenged the USPTO’s calculation of additional patent term for U.S. Patent No. 7,429,572. The dispute centered on whether the USPTO correctly deducted overlapping periods of “A delay” and “B delay” under 35 U.S.C. § 154(b). The district court upheld the USPTO’s calculation, and the Federal Circuit later affirmed in Gilead Sciences, Inc. v. Lee.[1][2]

What was Gilead Sciences v. Kappos about?

The case concerned the calculation of patent-term adjustment, or PTA, for Patent No. 7,429,572. PTA compensates a patent owner for certain USPTO delays during prosecution. It is separate from patent-term extension, which can apply to qualifying regulatory review periods for drugs and biological products.

Gilead argued that the USPTO had improperly reduced the patent’s PTA by treating certain prosecution delays as overlapping. The USPTO maintained that the statute required the agency to deduct overlapping delay periods so that the patent did not receive duplicate compensation for the same calendar days.

Item	Detail
Case	Gilead Sciences, Inc. v. Kappos
Court	U.S. District Court for the District of Columbia
Civil action	No. 1:12-cv-01090
Defendant	David J. Kappos, USPTO Director
Legal subject	Patent-term adjustment
Patent at issue	U.S. Patent No. 7,429,572
Primary statute	35 U.S.C. § 154(b)
Case type	Administrative review and summary judgment
Infringement claims	None
Generic defendant	None
Final appellate authority	Gilead Sciences, Inc. v. Lee, 778 F.3d 1341 (Fed. Cir. 2015)

The action did not determine whether a generic manufacturer infringed a Gilead patent. It determined how long the patent term should last after accounting for USPTO prosecution delay.

What patent was at issue in Gilead v. Kappos?

The dispute involved U.S. Patent No. 7,429,572. The patent issued on September 23, 2008, from an application filed on December 11, 1998.[3] The patent was assigned to Gilead Sciences and claimed pharmaceutical compounds and related subject matter relevant to Gilead’s antiviral portfolio.

The patent’s original twenty-year term was measured from the earliest effective U.S. nonprovisional filing date, subject to statutory adjustments. The contested PTA calculation affected the patent’s potential expiration date and therefore the period during which Gilead could exclude competitors.

The litigation record focused on the calculation methodology rather than on claim construction, validity, infringement, or pharmaceutical formulation scope. The case should therefore be analyzed as a patent-term case, not as a conventional Hatch-Waxman litigation.

What were the main legal issues?

The principal issue was how to calculate and offset different categories of USPTO delay.

What is “A delay” under 35 U.S.C. § 154(b)?

“A delay” generally compensates a patent applicant when the USPTO fails to meet specified examination deadlines. These deadlines include certain requirements relating to initial examination, responses, and actions on applications.

What is “B delay”?

“B delay” generally compensates for the USPTO’s failure to issue a patent within three years after the application’s filing date, subject to statutory exclusions and applicant-caused delays.

What is “C delay”?

“C delay” covers delays resulting from appeals, secrecy orders, and certain interference proceedings. C delay was not the central dispute in Gilead’s case.

Why did overlap matter?

Section 154(b)(2)(A) provides that the patent term adjustment period may not exceed the actual delay in issuing the patent and requires overlapping delay periods to be deducted. Gilead challenged the USPTO’s approach to identifying and subtracting overlap between A delay and B delay.

Gilead’s position would have produced a longer PTA period. The USPTO’s position treated the same calendar days as compensable only once. The practical effect was a shorter adjusted patent term than Gilead sought.

How did the district court rule?

The district court upheld the USPTO’s PTA calculation and rejected Gilead’s challenge.[1]

The court treated the USPTO’s interpretation of Section 154(b) as a reasonable reading of the statutory text. The court concluded that the agency could deduct overlapping A and B delay rather than award both categories for the same period.

The decision did not invalidate the patent. It did not narrow or cancel any patent claim. The ruling affected only the adjusted expiration date.

District court disposition

Issue	Gilead position	USPTO position	Result
A/B delay overlap	Overlap should not reduce the requested PTA to the extent argued by the USPTO	Overlapping days must be deducted	USPTO position upheld
Statutory interpretation	Gilead sought a longer term	USPTO applied a single-counting approach	Court found agency interpretation reasonable
Patent validity	Not at issue	Not at issue	No ruling
Infringement	Not at issue	Not at issue	No ruling
Damages	Not sought as infringement damages	Not applicable	No damages judgment

The court’s decision was important because it confirmed that PTA disputes could materially affect pharmaceutical exclusivity without involving a conventional patent infringement action.

What did the Federal Circuit decide?

The Federal Circuit affirmed the district court in Gilead Sciences, Inc. v. Lee.[2] By that point, David Kappos had been replaced as USPTO Director by Michelle K. Lee, which explains the change in caption.

The Federal Circuit held that the USPTO’s interpretation of the overlap provision was reasonable. The agency was permitted to calculate A delay and B delay and then subtract periods in which the categories overlapped.

The appellate decision reinforced several principles:

1. PTA is governed by the specific calculation rules in Section 154(b).
2. Separate delay categories do not necessarily produce additive term adjustments.
3. Overlapping calendar periods may be deducted.
4. Courts reviewing USPTO PTA decisions apply administrative-law principles rather than independently redesigning the agency’s calculation method.
5. The patent owner bears the burden of showing that the USPTO’s calculation was legally incorrect.

The Federal Circuit’s ruling reduced the value of Gilead’s challenge because the company could not obtain the additional term it sought.

What was the litigation timeline?

Date	Event
December 11, 1998	Application underlying Patent No. 7,429,572 filed
September 23, 2008	Patent No. 7,429,572 issued
2012	Gilead filed Civil Action No. 1:12-cv-01090 against USPTO Director Kappos
2013	District court upheld the USPTO’s PTA calculation
2014	Federal Circuit addressed related PTA interpretation issues in Novartis AG v. Lee
2015	Federal Circuit affirmed the judgment in Gilead Sciences, Inc. v. Lee

The related Federal Circuit decision in Novartis AG v. Lee provided important interpretive context for the calculation of B delay and the treatment of overlapping periods.[4] Gilead’s appellate outcome was consistent with the Federal Circuit’s broader approach to statutory PTA calculations.

When did the patent lose exclusivity?

The litigation did not establish a new commercial exclusivity date for a drug. It resolved the PTA calculation for Patent No. 7,429,572.

The patent’s base term was calculated from the relevant filing date, subject to PTA. The USPTO’s calculation remained in place after the district court and Federal Circuit decisions. Any analysis of the final enforceable term also would need to account for terminal disclaimers, maintenance fees, reexamination or post-grant proceedings, and any regulatory patent-term extension shown in the applicable patent and FDA records.

The key business conclusion is that Gilead did not obtain the longer patent term requested in the lawsuit.

What was the Orange Book status?

Gilead v. Kappos was not an Orange Book listing dispute. The complaint did not concern:

• Whether Patent No. 7,429,572 qualified for listing;
• Whether an ANDA applicant submitted a Paragraph IV certification;
• Whether FDA approval was blocked under the Hatch-Waxman stay;
• Whether Gilead obtained an infringement injunction;
• Whether a generic settlement agreement existed.

The Orange Book consequences, if any, would have depended on whether the patent was listed for a specific approved product and whether its claims met FDA listing requirements. The PTA ruling itself did not decide those questions.[5]

Did the case involve a Paragraph IV challenge?

No. There was no ANDA defendant and no Paragraph IV certification in the litigation. The case therefore did not establish a generic launch date, a 30-month stay, or a first-filer exclusivity position.

This distinction is commercially significant. A patent-term victory in a district court PTA action can extend the period during which a patent may be available for enforcement, but it does not itself create an Orange Book block or establish infringement against a generic applicant.

What formulation and method-of-use patents were litigated?

None were litigated in this action. The case did not involve a claim-by-claim assessment of:

• Active pharmaceutical ingredient claims;
• Salt, ester, or polymorph claims;
• Tablet or capsule formulation claims;
• Fixed-dose combination claims;
• Dosing-regimen claims;
• Treatment or method-of-use claims;
• Manufacturing-process claims;
• Drug-delivery technology.

The relevant IP question was term duration for Patent No. 7,429,572. Patent strength in the conventional sense, including validity, claim breadth, written description, enablement, and infringement risk, was outside the case’s scope.

How strong was Gilead’s patent position after the ruling?

The ruling preserved the USPTO’s original PTA calculation but did not adjudicate the patent’s validity or enforceability. The decision therefore provided a limited form of patent-estate support.

Strengths

• The patent remained in force for the term calculated by the USPTO.
• The Federal Circuit endorsed the agency’s statutory interpretation.
• The decision reduced the risk that the patent term would be shortened through the specific PTA challenge.
• The ruling confirmed that overlapping USPTO delays would not automatically produce additional term.

Limitations

• The case did not test the patent against an accused generic product.
• No court evaluated infringement.
• No claim construction decision defined the patent’s commercial scope.
• No ruling addressed obviousness, anticipation, written description, or enablement.
• The decision did not resolve Orange Book eligibility or regulatory exclusivity.

The patent estate’s commercial strength therefore depended on matters not decided in Gilead v. Kappos, including the patent’s relationship to approved products, other Gilead patents, and any later generic challenges.

What generic-entry risks existed?

The case did not produce a generic-entry judgment. Generic-entry risk had to be assessed separately through:

1. The final expiration date of Patent No. 7,429,572;
2. Any other Orange Book-listed patents;
3. The scope of active-ingredient and formulation claims;
4. Paragraph IV certifications;
5. Potential patent-term extension;
6. Pediatric exclusivity or other regulatory exclusivity;
7. Patent litigation filed against ANDA applicants;
8. Settlement agreements and licensed launch dates.

Because Gilead lost its request for additional PTA, the company did not gain the incremental exclusivity period it sought. That result was unfavorable to any strategy dependent on extending the patent term through administrative review.

Did the case involve licensing or settlement agreements?

No licensing agreement or generic settlement agreement was adjudicated in the reported litigation. The record was directed to the USPTO’s term calculation.

The absence of a settlement is relevant to market-entry analysis. There was no judicially approved generic launch date and no reported agreement converting the PTA dispute into a commercial license.

What was the revenue exposure?

The case did not award damages or determine product revenue. Its financial significance was the potential value of additional patent life.

A PTA increase could have affected:

• The timing of generic competition;
• Branded product price erosion;
• Inventory and contracting strategy;
• Royalty or license payments;
• Forecast revenue during the disputed term;
• The value of related Gilead products protected by overlapping patents.

Because the court rejected Gilead’s attempt to obtain additional term, the company did not receive the incremental revenue protection associated with the longer term it requested. The case itself did not quantify lost revenue or impose a financial liability on the USPTO.

Key Takeaways

• Gilead Sciences v. Kappos was a patent-term adjustment case, not an infringement action.
• The dispute involved U.S. Patent No. 7,429,572.
• Gilead challenged the USPTO’s deduction of overlapping A delay and B delay.
• The district court upheld the USPTO’s calculation.
• The Federal Circuit affirmed in Gilead Sciences v. Lee.
• The case did not involve an ANDA, Paragraph IV certification, Orange Book listing, formulation patent, method-of-use patent, generic settlement, or licensing agreement.
• The ruling preserved the USPTO’s PTA calculation but did not determine patent validity, infringement, or commercial claim scope.
• Gilead did not obtain the additional patent term it sought.

FAQs About Gilead Sciences v. Kappos

What was the patent number in Gilead Sciences v. Kappos?

The case involved U.S. Patent No. 7,429,572, assigned to Gilead Sciences.

Was Gilead v. Kappos a Hatch-Waxman lawsuit?

No. It was an administrative patent-term review action against the USPTO Director. No ANDA applicant was named as a defendant.

Did Gilead win the patent-term adjustment dispute?

No. The district court upheld the USPTO’s calculation, and the Federal Circuit affirmed.

Did the decision invalidate any Gilead patent claims?

No. The litigation did not address patent validity, claim construction, infringement, or enforceability.

What is the controlling appellate case?

The controlling appellate decision is Gilead Sciences, Inc. v. Lee, 778 F.3d 1341 (Fed. Cir. 2015), which affirmed the USPTO’s treatment of overlapping patent-term adjustment delays.

References

1. Gilead Sciences, Inc. v. Kappos, No. 1:12-cv-01090, U.S. District Court for the District of Columbia (2013).

2. Gilead Sciences, Inc. v. Lee, 778 F.3d 1341. United States Court of Appeals for the Federal Circuit (2015).

3. United States Patent and Trademark Office. (2008). U.S. Patent No. 7,429,572.

4. Novartis AG v. Lee, 740 F.3d 593. United States Court of Appeals for the Federal Circuit (2014).

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.